Grants
A specialized center program of four phase I and II clinical trials and one epidemiological study. The goal of SPOTRIAS is to reduce disability and mortality in acute stroke patients through the development of improved treatment by laboratory investigation into the biology of stroke, clinical investigation of new therapies based on these laboratory studies, and assessment of outcome and improved application of effective therapies. Secure web applications update the SPOTRIAS database.
Sponsored by the National Institute of Neurological Disorders and Stroke (NINDS); 2002-2007 ($640,877).
ETROP is a multicenter study in 26 centers with a natural history study that is determining the incidence of retinopathy of prematurity and a randomized clinical trial that is determining the safety and efficacy of early treatment of retinopathy of prematurity in 400 premature infants.
Sponsored by the National Eye Institute (NEI); 1999-2009 ($18,405,455).
A prospective study that examines the association between selected hypertensive genes and coronary heart diseases modified by the type of antihypertensive treatment. GENHAT is an ancillary study of ALLHAT(see below).
Sponsored by the National Heart, Lung, and Blood Institute (NHLBI); 1999-2004 ($1,474,101).
A practice-based randomized clinical trial of antihypertensive pharmacological treatment in more than 600 office-based practices and general medical and specialty clinics in the U.S., Puerto Rico, the Virgin Islands, and Canada. It had two components:
- An antihypertensive component, to determine whether newer antihypertensive agents, such as ACE inhibitors, calcium blockers, and alpha blockers, reduce incidence of coronary heart disease (CHD) in high-risk hypertensives when compared to diuretics.
- A lipid-lowering component, to determine whether reduction of serum cholesterol with pravastatin, an HMG-CoA reductase inhibitor, reduces total mortality in moderately hypercholesterolemic older hypertensives.
Sponsored by the National Heart, Lung and Blood Institute (NHLBI); 1993-2008 ($101,198,107). ALLHAT Papers
